SCHEMBL5526372

SCHEMBL5526372

CSCC[C@H](NC(=O)c1ccccc1)C(=O)N(C)C#N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.55
ALDH1A1 P00352 1/20 0.55
CRHBP P24387 1/20 0.55
KMT2A Q03164 1/20 0.55
CRHR2 Q13324 1/20 0.55
CTSB P07858 4/20 0.51
NPC1 O15118 1/20 0.49
CTSL P07711 3/20 0.48
CTSS P25774 3/20 0.48
CTSK P43235 3/20 0.48
CTSF Q9UBX1 1/20 0.48
CA2 P00918 3/20 0.48
CA1 P00915 2/20 0.48
LMNA P02545 2/20 0.47
TSHR P16473 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CCR1 P32246 1/20 0.46
CA12 O43570 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6020007 0.89 CTSL (0.51) MEN1ALDH1A1CRHBPKMT2ACRHR2
SCHEMBL7552956 0.88 CTSL (0.47) MEN1ALDH1A1CRHBPKMT2ACRHR2
SCHEMBL5529192 0.84 HPGD (0.56) MEN1KMT2ACTSBCTSLCTSS
SCHEMBL5524025 0.83 LMNA (0.52) MEN1KMT2ACTSBNPC1CTSL
SCHEMBL7560030 0.82 CTSL (0.47) MEN1KMT2ACTSBCTSLCTSS
SCHEMBL5527592 0.82 CTSL (0.50) MEN1KMT2ACTSBNPC1CTSL
Water SCHEMBL28867161 0.82 CA2 (0.67) MEN1ALDH1A1CRHBPKMT2ACRHR2
SCHEMBL6021764 0.81 CTSL (0.64) CTSBCTSLCTSSCTSKCTSF
SCHEMBL5517750 0.81 CTSL (0.64) CTSBCTSLCTSSCTSKCTSF
SCHEMBL7472684 0.81 CTSL (0.47) MEN1KMT2ACTSBNPC1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2007-01-18 US disclosed
US-20040147745-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2004-07-29 US disclosed
EP-1178958-B1 N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2004-02-18 EP disclosed
US-20030096796-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-05-22 US disclosed
US-6455502-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096796-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 MEN1 3977/4885ALDH1A1 4049/4885CRHBP 2259/4885
US-20040147745-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 MEN1 3977/4885ALDH1A1 4049/4885CRHBP 2259/4885
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS CTRL, SERPINB1, CPN1 MEN1 3977/4885ALDH1A1 4049/4885CRHBP 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.